Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2011

View Archived Issues

Interim first-in-human data released on two c-Met inhibitors

Trial determines phase II doses of ixabepilone/cisplatin combination regimen in NSCLC

Halozyme discloses clinical results on new Herceptin formulation

Pulmonary Fibrosis Foundation to fund independent evaluation of Compugen's candidate for IPF

Orantinib advances through studies in NSCLC and breast cancer

U.S. universities assess CDME in model of cystinuria

Analyses focus on cardiovascular risk with naltrexone/bupropion

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Phase I study of PPI-668 commences

CSIR presents new antitumor agents

Takeda commences international phase III program for TAK-875

Lpath begins dosing in second proof-of-concept iSONEP trial

Studies confirm efficacy of Transcend-trastuzumab conjugate in HER2-positive breast cancer

Encore Therapeutics completes proof-of-concept study of ETI-511

Novel vitamin D receptor ligands synthesized at WARF

FDA clears IsoAmp HSV assay

Nile Therapeutics completes dosing in subcutaneous cenderitide trial

Phase I MultiStem study advances

Actelion Pharmaceuticals reports new prostanoid DP2 receptor antagonists

FDA approves MethylGene's IND for new study of antifungal product candidate

Lux Biosciences withdraws Luveniq MAA

Almirall and Lundbeck enter agreement to copromote escitalopram

EMA delays review of Flutiform MAA

Isotechnika receives scientific advice from EMA for voclosporin trial

Malaria vaccine RTS,S/ASO1E shows efficacy in African children

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.